The strategic approach of the Biodiagnostic Sciences and Technologies Division for the next five years is mainly related with the Smart Specialization Priority: Health-Pharmaceutics, and aims to perform high quality basic and applied R&D targeting specific applications of high scientific, technological, and societal impact and to develop/sustain the respective infrastructure. Over the last decade, the roadmap integrating the main activities of the Biodiagnostics team has been summarized in the key-phrase:
“from chromosomes and genes … to proteins … and biosensing devices”-
